United States securities and exchange commission logo





                           July 7, 2022

       Emil Michael
       President
       D-Wave Quantum Inc.
       3033 Beta Avenue
       Burnaby, British Columbia V5G 4M9
       Canada

                                                        Re: D-Wave Quantum Inc.
                                                            Amendment No. 3 to
Registration Statement on Form S-4
                                                            Filed June 24, 2022
                                                            File No. 333-263573

       Dear Mr. Michael:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.
Unless we note
       otherwise, our references to prior comments are to comments in our June
9, 2022 letter.

       Amendment No. 3 to Registration Statement on Form S-4/A filed June 24,
2022

       Sponsor Support Agreement, page 27

   1.                                                   We note your disclosure
that "D-Wave may allocate up to 3,287,762 D-Wave Quantum
                                                        Common Shares if D-Wave
determines, in its sole discretion following consultation with
                                                        DPCM, that such
allocation would be advisable in connection with the consummation of
                                                        the Transaction."
Please clarify to whom or for what purpose these shares will be
                                                        allocated.
 Emil Michael
FirstName   LastNameEmil Michael
D-Wave Quantum     Inc.
Comapany
July 7, 2022NameD-Wave Quantum Inc.
July 7,2 2022 Page 2
Page
FirstName LastName
Risk Factors
We expect to require additional capital to pursue our business objectives. . .
, page 54

2.       Please specify the price floor beneath which D-Wave Quantum may not
sell to Lincoln
         Park any D-Wave Quantum Common Shares.
Resignation of Financial and Capital Markets Advisors, page 117

3.       We note your disclosure on page 117 describing how the DPCM Board
assessed the
         potential impact of the resignations of Morgan Stanley, Citi, and UBS
(the "Firms"),
         including how "the services to be provided by each of Morgan Stanley
and Citi were
         substantially complete, and UBS    services in connection with the
deferred underwriting
         commission were completed when the DPCM IPO was completed." Please
clarify here
         whether the DPCM Board viewed the services to be provided by UBS, in
its role as capital
         markets advisor, as substantially complete and how it assessed UBS'
resignation
         specifically in this role.
Extension; Waiver, page 280

4.       Please file a copy of the waiver whereby D-Wave agreed to waive the
minimum cash
         condition as an exhibit to your registration statement.
Background of the Transaction, page 287

5.       We note your disclosure that on June 16, 2022, after discussions
between D-Wave and
         DPCM, the parties agreed to modify several terms of the Transaction
and enter a Purchase
         Agreement with Lincoln Park. Revise your disclosure of the background
of the
         Transaction to identify the persons involved in these discussions and
summarize the
         material aspects of any negotiations.
6.       Please identify the "financial advisor" who participated in the
meeting with the Sponsor
         and DPCM's management team on August 25, 2021. Refer to prior comment
11.
General

7.       With a view toward disclosure, please tell us whether your sponsor is,
is controlled by, or
         has substantial ties with a non-U.S. person. Please also tell us
whether anyone or any
         entity associated with or otherwise involved in the transaction, is,
is controlled by, or has
         substantial ties with a non-U.S. person. If so, also include risk
factor disclosure that
         addresses how this fact could impact your ability to complete your
initial business
         combination. For instance, discuss the risk to investors that you may
not be able to
         complete an initial business combination with a U.S. target company
should the
         transaction be subject to review by a U.S. government entity, such as
the Committee on
         Foreign Investment in the United States (CFIUS), or ultimately
prohibited. Further,
         disclose that the time necessary for government review of the
transaction or a decision to
         prohibit the transaction could prevent you from completing an initial
business
 Emil Michael
D-Wave Quantum Inc.
July 7, 2022
Page 3
      combination and require you to liquidate. Disclose the consequences of
liquidation to
      investors, such as the losses of the investment opportunity in a target
company, any price
      appreciation in the combined company, and the warrants, which would
expire worthless.
8.    We note your response to prior comments 11 and 14. Please discuss the
material terms of
      your obligations and any applicable indemnification or contribution
provisions under your
      advisory agreements and engagement letters with Morgan Stanley, Citi and
UBS
      (including the underwriting agreement with UBS) that survive the
resignation of the
      Firms. Include appropriate risk factor disclosure about any impact these
surviving
      provisions and obligations may have on the company. Additionally, discuss
the scope of
      the work agreed to be performed by each Firm further to their engagement
letter with
      you.
9.    Please revise the disclosure of your proxy statement/prospectus to note
that Citi and
      Morgan Stanley were each entitled to a placement fee equal to 2.00% of
the gross
      proceeds received by the Company upon consummation of the PIPE Financing.
10.   Please disclose whether the Firms assisted in the preparation or review
of any materials
      reviewed by DPCM's Board or management as part of their services and
whether any such
      Firm has withdrawn its association with those materials and notified the
DPCM Board of
      such disassociation. If so, include, for context, that there are similar
circumstances in
      which a financial institution is named and that the firm's resignation
indicates it is not
      willing to have the liability associated with such work. Additionally,
revise your
      disclosure to state whether the DPCM Board relied on any materials or
work product
      provided by the Firms.
11.   Disclose whether there are any costs that will result from the
resignations of the
      Firms (such as additional costs to engage another service provider) and
whether the
      resignations will affect the timing of the Transaction.
        You may contact Lisa Etheredge, Senior Staff Accountant, at (202)
551-3424 or Robert
Littlepage, Accounting Branch Chief, at (202) 551-3361 if you have questions
regarding
comments on the financial statements and related matters. Please contact
Patrick Faller, Staff
Attorney, at (202) 551-4438 or Jan Woo, Legal Branch Chief, at (202) 551-3453
with any other
questions.



                                                           Sincerely,
FirstName LastNameEmil Michael
                                                           Division of
Corporation Finance
Comapany NameD-Wave Quantum Inc.
                                                           Office of Technology
July 7, 2022 Page 3
cc:       Adam M. Givertz
FirstName LastName